• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Top Five Radiology Video Interviews — January 2025

Commentary
Slideshow

Catch up on the most well-viewed video interviews from Diagnostic Imaging in January 2025.

As we come to the end of January, we take a look back at the most viewed video interviews of the past month with topics ranging from the recent FDA guidance on AI-enabled devices and new appropriate use criteria on brain PET imaging to legislative priorities in radiology and image-based risk assessment AI algorithms. Review the slideshow below to see highlighted video interviews from January 2025.

Recent Videos
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Related Content
Multimodal AI with CCTA and MRI Data Shows Promise in Predicting MACE in Patients with Obstructive CAD

Multimodal AI with CCTA and MRI Data Shows Promise in Predicting MACE in Patients with Obstructive CAD

Jeff Hall
January 29th 2025
Article

For patients with newly diagnosed obstructive coronary artery disease (CAD), a multimodal machine learning model offered an 86 percent AUC for predicting MACE, which was 10 percent higher than CCTA alone and over 35 percent higher than the Framingham Risk Score.

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 3

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 3

Jeff Hall
September 1st 2023
Podcast

In the third episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss the challenges of expanded breast cancer screening amid a backdrop of radiologist shortages and ever-increasing volume on radiology worklists.

FDA Clears AI-Enhanced Portfolio of Ultrasound Systems for Women with High-Risk Pregnancies

FDA Clears AI-Enhanced Portfolio of Ultrasound Systems for Women with High-Risk Pregnancies

Jeff Hall
January 28th 2025
Article

An array of AI-powered features and automated tools may lead to improved workflow and image quality with the Voluson Expert 22, 20 and 18 ultrasound systems.

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 2

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 2

Jeff Hall
August 23rd 2023
Podcast

In the second episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss recent studies published by the Journal of the American Medical Association (JAMA) that suggested moving to more of a risk-adapted model for mammography screening.

Clarius Unveils Updated Ultrasound Software to Enhance Workflows

Clarius Unveils Updated Ultrasound Software to Enhance Workflows

Jeff Hall
January 22nd 2025
Article

The latest ultrasound software update from Clarius includes new artificial intelligence (AI) capabilities, coding assistance and a variety of advances tailored to different fields of medicine.

PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis

PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis

Jeff Hall
January 22nd 2025
Article

Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.

© 2025 MJH Life Sciences

All rights reserved.